Ligandy receptorów gabaergicznych : struktura, właściwości, możliwość zastosowania w terapii

• Autorzy: Malawska B. , Więckowski K.

Warianty tytułu

EN

Ligands of gaba-ergic receptors : the structure, properties and therapeutic prospects

• Języki publikacji: PL

Abstrakty

EN

This review attempts to briefly summarize the recent development in the study of ?-aminobutyric (GABA) receptors, and their ligands. The search on compounds with agonistic and antagonistic properties of GABA receptors, the structure activity relationships, and therapeutic prospects of GABA receptors ligands was also described. GABA is the major inhibitory neurotransmitter in the brain [1-6], and influences neurons via a large number of receptor subtypes which are grouped on the basis of their pharmacology under three major classes of receptors: GABAA, GABAB, and GABAC. GABAA and GABAC receptors are ligand gated ion channels, while GABAB receptors are G-protein coupled receptors [7-10]. These receptors, especially GABAA receptors, are involved in neurological and psychiatric disorders, and are therapeutic targets in certain diseases. Several different binding sites on GABAA receptors were proposed, these include agonist sites [11-14], which also recognize competitive antagonists [15], and many positive or negative modulators sites [16-20]. GABAA receptors are modulated by benzodiazepines [21-26], barbiturates, neurosteroides [27], klomethiazol [28, 29], anesthetics [30-33], ethanol [34], some insecticides [35], furosemide [36], Zn2+ iones [37], and sites for other compounds [38-40]. Some ligands of GABAB and GABAC receptors are also presented [41-44].

Słowa kluczowe

PL

ligandy receptora GABA; oddziaływanie na receptory

EN

GABA receptors; interaction with receptors

• Wydawca: Polskie Towarzystwo Chemiczne
• Czasopismo: Wiadomości Chemiczne
• Rocznik: 2004
• Tom: [Z] 58, 7-8
• Strony: 571--598
• Opis fizyczny: Bibliogr. 53 poz., schem.

Twórcy

autor

Malawska B.

• Katedra Chemii Farmaceutycznej Collegium Medicum Uniwersytetu Jagiellońskiego, ul. Medyczna 9, 30-688 Kraków

autor

Więckowski K.

• Katedra Chemii Farmaceutycznej Collegium Medicum Uniwersytetu Jagiellońskiego, ul. Medyczna 9, 30-688 Kraków

Bibliografia

• [1] S. Konturek, Fizjologia człowieka, t. I. Fizjologia ogólna., Wyd. VI, Fundacja dla Wydziału Lekarskiego UJ, Kraków 1995.
• [2] W. Kostowski, Farmakologia. Podstawy farmakoterapii., Wydawnictwo Lekarskie PZWL, Warszawa 1998,2001.
• [3] E. Roberts, GABA in nervous system function. Raven Press, New York, 1976.
• [4] B. Malawska, Wiad. Chem., 1989, 43,457.
• [5] P. Krogsgaard-Larsen, B. Frølund, F. S. Jørgensen, A. Schousboe, J. Med. Chem. 1994,37, 2489.
• [6] J.Z. Nowak, J.B. Zawilska, (red), Receptory - struktura, charakterystyka, funkcja. PWN, Warszawa, 1997.
• [7] L. Coyne, G. Lees, Curr. Anaesth. Crit. Care, 2002,13, 334.
• [8] M. Chebib, G.A.R. Johnston, J. Med. Chem., 2000,43, 1428.
• [9] L Bohme, H. Luddens, Curr. Med. Chem., 2001,8, 1258.
• [10] A. Zejc, M. Gorczyca Chemia lekó, Wydawnictwo Lekarskie PZWL, Warszawa 2002.
• [11] E.R. Korpi, R.M. Mihalek, S.T. Sinkkonen, B. Hauer, W. Hevers, G.E. Homanics, W. Sieghart, H. Luddens, Neuroscience, 2002,109,733.
• [12] E. Sigel, R.H. Dodd, Drugs Fut., 2001,26, 1191.
• [13] E. Sanna, F. Busonero, G. Talani, M. Carta, F. Massa, M. Peis, E. Maciocco, G. Biggio, Eur. J. Pharmacol., 2002,451, 103.
• [14] P.R. Carlier, E.S.-H. Chow, R.L. Barlow, J.R. Bloomquist, Biooig. Med. Chem. Lett., 2002, 12, 1985.
• [15] B. Frølund, L. Tagmose, A. T. Jørgensen, U. Kristiansen, T. B. Stensb0l, T. Liljefors, P. Krogsgaard-Larsen, Eur. J. Med. Chem., 2003, 38,447.
• [16] X.-L. Ju, Y. Ozoe, bioorg. Med. Chem., 2000, 8,2337.
• [17] D.I. Obradovič, D.R. Bokonjič, M.M. Savič, D.S. Andjelkovič, N.D. Ugrešič, M.R Stojilkovič, Pharmacol. Res., 2002,46, 149.
• [ 18] D.J. Canney K.D. Holland, J.A. Levine, A.C. McKeon, J.A. Ferrendelli, D.R Covey, I. Med. Chem., 1991,34,1460.
• [19] E.M. Petersen, K. Xu, K.D. Holland, A.C. McKean, S.M. Rothman, J.A. Ferrendelli, D.F. Covey, J. Med. Chem., 1994,37,275.
• [20] D.J. Canney, H.-F. Lu, A.C. McKeoan, K.-W. Yoon, K. Xu, K.D. Holland, S.M. Rothman, J.A. Ferrendelli, D.F. Covey, Bioorg. Med. Chem., 1998, 6, 43.
• [21] L.A. Sorbera, P.A. Leeson, J. Silvestre, J. Castaner, Drugs Fut., 2001,26, 651.
• [22] Q. Wang, Y. Han, H. Xue, CNS Drug Rev., 1999,5, 125.
• [23] S. Selleri, F. Bruni, C. Costagli, A. Costanzo, G. Guerrini, G. Ciciani, P. Gratteri, C. Bonaccini, P. Malmberg Aiello, F. Besnard, S. Renard, B. Costa, C. Martini, J. Med. Chem., 2003,46,310.
• [24] M.S. Chambers, J.R. Atack, F.A. Bromidge, H.B. Brughton, S. Cook, G.R. Dawson, S.C Hobbs, K.A. Maubach, A.J.Reeve, G.R.Seabrook, K. Wafford, A.M. MacLeod, J. Med. Chem., 2002,45, 1176.
• [25] P.A. Albaugh, L. Marshal, J. Gregory, G. White, A. Hutchison, P.C. Ross, D. W. Gallagher, J.F. Tallman, M. Crago, J.V. Casella, J. Med. Chem., 2002,45, 5043.
• [26] T. Akbarzadeh, S.A. Tabatabi, M.J. Khoshnoud, J. Mohammad, B. Shafaghi, A. Shafiee, Bioorg. Med. Chem., 2003,11, 769.
• [27] I. Collins, Ch. Moyes, W.B. Davey, M. Rowley, F.A. Bromidge K. Quirk, J.R. Atack, R.M. Mckernan, S.-A. Thompson, K. Wafford, G.R. Dawson, A. Pike, B. Sohal, N.N. Tsou, R.G. Ball, J.L. Castro, J. Med. Chem., 2002,45, 1887.
• [28] X. Li, Ch. Zhang, R. Furtmueller, K. Fuchs, S. Huck, W. Sieghart, J. Deschamps, J.M. Cook, J. Med. Chem., 2003,46, 5567.
• [29] P. Kahnberg, E. Lager, C. Rosenberg, J. Schougaard, L. Camet, O. Sterner, E.0. Nielsen, M. Nielsen, T. Liljefors, J. Med. Chem., 2002,45,4188.
• [30] M.S. Huen, K.-M. Hui, J.W.C. Leung, E. Sigel, R. Baur, J.T.-F. Wong, Biochem. Pharmacol., 2003, 66, 2397.
• [31] K.-M. Hui, M.S. Huen, H. Y. Wang, H. Zheng, E. Sigel, R. Baur, H. Ren, Z. Wang Li, J.T.-F. Wong, H. Xue, Biochem. Pharmacol., 2002, 64, 1415.
• [32] M. Vergnes, A. Boehrer, Xiaohui He, H. Greney, M. Dontenwill, J. Cook, C. Marescaux, Epilepsy Res., 2001,47,43.
• [33] J.F. Navarro, E. Buron, M. Martin-Lopez, Progr. Neuro-Psychopharmacol. Biol. Psychiatry, 2002, 26 1389.
• [34] F. Crestani, R. Assandri, M. Tauber, J. R. Martin, U. Rudolph, Neuropharmacology, 2002,43,679.
• [35] W. Wang, D.-Ch. Wu, Y.-H. Chen, W. He, L.-Ch. Yu, Brain Res., 2002,956,393.
• [36] R. Rupprecht, Psychoneuroendocrin., 2003,28,139.
• [37] P. Yang, B. L. Jones, L. P. Henderson, Neuropharmacology, 2002,43, 619.
• [38] R.M. Nelson, A.H. Hainsworth, D.G. Lambert, J.A. Jones, T.K. Murray, D.A. Richards, J. Gabrielsson, A.J. Cross, A.R. Green, Neuropharmacology, 2001, 41, 159.
• [39] R.M. Nelson, A.R. Green, A.H. Hainsworth, Eur. J. Pharmacol., 2002, 452,255.
• [40] S.M. O’Shea, L.C. Wong, N.L. Harrison, Brain Res., 2000,852, 344.
• [41] A. Anderson, D. Belelli, D.J. Bennett, K.I. Buchanan, A. Casula, A. Cooke, H. Feilden, David K. Ge„ell, N.M. Hamilton. E.J. Hutchinson, J.J. Lambert, M.S. Maidment, R. McGuire, P. McPhail, S. Miller, A. Muntoni, J.A. Peters, F.H. Sansbury, D. Stevenson, H. Sundaram, J. Med. Chem., 2001,44, 3582.
• [42] B.D. Harris, E.J. Moody, P. Skolnick, Eur. J. Pharmacol., 1998,341,349.
• [43] T.P. Piepponen, K. Kiianmaa, L. Ahtee, Pharmacol. Biochem. Behav., 2002, 74, 21.
• [44] C. Vale, E. Fonfria, J. Bujons, A. Messeguer, E. Rodriguez-Farre, C. Sunol, Neuroscience, 2003, 117,397.
• [45] A. Guyon, L. Cathala, D. Paupardin-Tritsch, D. Eugene, Neuropharmacology, 2002,43, 750.
• [46] A. Barberis, E.M. Petrini, E. Cherubini, J. W. Mozrzymas, Neuropharmacology, 2002, 43, 607.
• [47] C.M. van Rijn, E. Willems-van Bree, Eur. J. Pharmacol., 2003,464, 95.
• [48] N. Rezai, C. Duggan, D. Cairns, G. Lees, P. L. Chazot, Biochem. Pharmacol., 2003, 65, 619.
• [49] G. Lees, P.L. Chazot, H. Vankayalapati, G. Singh, Bioorg. Med. Chem. Lett., 2000,10, 1759.
• [50] F. Wang, J. Li, Ch. Wu, J. Yang, F. Xu, Q. Zhao, Pharmacol. Biochem. Behavior., 2003, 74, 573.
• [51] H. Mohler, D. Benke, J.-M. Fritschy, Life Sei., 2001, 68,2297.
• [52] P.V. Dicpinigatis, Pulmon. Pharmacol. Ther., 1999,12, 257.
• [53] M.S. Cousins, D.C.S. Roberts, H. de Wit, Drug Alcohol Dependence, 2002,65,209.